SCHEMBL1428069

SCHEMBL1428069

CC(C)(C)N(CC1CCN(CCNS(=O)(=O)C(F)(F)F)CC1)C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.34
HTR4 Q13639 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
KCNH2 Q12809 2/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
CYP1A2 P05177 1/20 0.32
ALOX15 P16050 1/20 0.32
NFKB1 P19838 1/20 0.32
PMP22 Q01453 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CACNA1I Q9P0X4 1/20 0.32
CARM1 Q86X55 1/20 0.32
PRMT6 Q96LA8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1428097 0.85 KDM1A (0.41) CYP2C9HTR4MEN1ALDH1A1CYP3A4
SCHEMBL4220843 0.81 CCR5 (0.38) KCNH2
SCHEMBL4220846 0.77 KCNH2 (0.39) HTR4ALDH1A1CYP2D6KCNH2CACNA1I
SCHEMBL1430766 0.76 PRMT3 (0.40) ALOX15CARM1PRMT6
SCHEMBL1432068 0.74 NCF1 (0.38) CYP2C9HTR4MEN1ALDH1A1CYP3A4
SCHEMBL7803943 0.74 DRD2 (0.43) HTR4CYP2D6KCNH2DRD2CACNA1I
Hydrochloric Acid SCHEMBL1430748 0.73 NCF1 (0.37) CYP2C9HTR4MEN1ALDH1A1CYP3A4
SCHEMBL1428067 0.72 EPHX1 (0.34) KCNH2HTR1ADRD2DRD4ALOX15
SCHEMBL17711644 0.72 POLB (0.42) MEN1ALDH1A1KMT2ANPSR1
SCHEMBL27888773 0.71 CCR5 (0.41) HTR4MEN1ALDH1A1KMT2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065926-A1 N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. 2013-03-14 US disclosed
EP-2300007-A1 N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Zalicus Pharmaceuticals Ltd. (CA) 2011-03-30 EP disclosed
WO-2009146540-A1 N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD (CA) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065926-A1 N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1G, CACNA1H, CACNA1B CYP2C9 3319/4885HTR4 1724/4885MEN1 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.